Physician profile
Sandra E Scholebo
NPI 1437168622
$10,863.83
in general payments reported to CMS, 2019-2025
31 companies · $2,870 in 2025
The $2,870 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,479 · 2022: $1,571 · 2023: $2,060 · 2024: $2,884 · 2025: $2,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,105 · Education: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,105.00 |
| Education | $708.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,365.93 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,182.78 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,017.50 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $920.82 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $904.21 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $809.72 | 2022-2025 | Ilumya, Winlevi |
| Ucb, INC. | $674.11 | 2021-2025 | Bimzelx |
| Genzyme Corporation | $514.24 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $503.51 | 2022-2024 | Sotyktu |
| Incyte Corporation | $475.95 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $430.02 | 2021-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $418.76 | 2022-2024 | Vtama |
| Prugen, INC. Pharmaceuticals | $280.00 | 2021 | |
| Arcutis Biotherapeutics, INC. | $218.90 | 2023-2025 | Zoryve |
| Pfizer INC. | $188.23 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $136.31 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $128.61 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $105.51 | 2024-2025 | Jublia, Cabtreo, Arazlo |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Amgen INC. | $65.92 | 2022-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $51.97 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $51.47 | 2021 | |
| Epi Health, LLC | $48.19 | 2021-2022 | |
| Kerecis Limited | $27.02 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Lnhc, INC | $24.72 | 2025 | Zelsuvmi |
| Almirall LLC | $24.23 | 2021 | |
| Biofrontera INC. | $22.38 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Cipher Pharmaceuticals US LLC | $22.32 | 2025 | Spinosad, Natroba |
| Organogenesis INC. | $17.91 | 2025 | Cygnus Dual |
| Genentech USA, INC. | $17.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Scholebo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.